Profound Medical to Highlight TULSA-PRO and iMRI Innovations at AUA2026
Event summary
- Profound Medical will showcase TULSA-PRO and the TULSA Procedure at AUA2026 with four oral presentations on May 16, 2026.
- The company will demonstrate TULSA-PRO and display a Siemens MAGNETOM Free.Max MR.1 at Booth #413.
- Profound is exploring the integration of PSMA PET imaging with the TULSA Procedure for enhanced treatment planning.
- TULSA-PRO is cleared by the FDA and approved in major global markets for prostate ablation.
The big picture
Profound Medical's focus on interventional MRI (iMRI) procedures aligns with the growing demand for minimally invasive, precision treatments in prostate cancer. The company's TULSA-PRO platform offers a unique, incision-free approach that minimizes side effects, positioning it as a key player in the evolving landscape of prostate cancer therapies. The exploration of PSMA PET imaging integration further underscores the potential for enhanced treatment planning and monitoring, potentially expanding the platform's applications.
What we're watching
- Integration Potential
- How the integration of PSMA PET imaging with TULSA-PRO will enhance treatment precision and planning.
- Market Expansion
- The pace at which Profound Medical can expand the commercial availability of TULSA-PRO in new markets.
- Clinical Adoption
- Whether the TULSA Procedure will gain broader acceptance among urologists for prostate cancer treatment.